{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:24:02Z","timestamp":1770434642068,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,4,16]],"date-time":"2008-04-16T00:00:00Z","timestamp":1208304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Von Hippel-Lindau disease (VHL) is a rare autosomal dominant disease characterized by development of cystic and tumorous lesions at multiple sites, including the brain, spinal cord, kidneys, adrenals, pancreas, epididymis and eyes. The clinical phenotype results from molecular abnormalities of the <jats:italic>VHL<\/jats:italic> tumor suppressor gene, mapped to human chromosome 3p25-26. The <jats:italic>VHL<\/jats:italic> gene encodes two functionally active VHL proteins due to the presence of two translational initiation sites separated by 53 codons. The majority of disease-causing mutations have been detected downstream of the second translational initiation site, but there are conflicting data as to whether few mutations located in the first 53 codons, such as the Pro25Leu could have a pathogenic role. In this paper we report a large Hungarian VHL type 2 family consisting of 32 members in whom a disease-causing AGT80AAT (Ser80Ile) c.239G&gt;A, p.Ser80Ile mutation, but not the concurrent CCT25CTT (Pro25Leu) c.74C&gt;T, p.Pro25Leu variant co-segregated with the disease. To our knowledge, the Ser80Ile mutation has not been previously described in VHL type 2 patients with high risk of pheochromocytoma and renal cell cancer. Therefore, this finding represents a novel genotype-phenotype association and VHL kindreds with Ser80Ile mutation will require careful surveillance for pheochromocytoma. We concluded that the Pro25Leu variant is a rare, neutral variant, but the presence such a rare gene variant may make genetic counseling difficult.<\/jats:p>","DOI":"10.1186\/1471-2350-9-29","type":"journal-article","created":{"date-parts":[[2008,5,2]],"date-time":"2008-05-02T01:13:06Z","timestamp":1209690786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family"],"prefix":"10.1186","volume":"9","author":[{"given":"Attila","family":"Patocs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gergics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miklos","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferenc","family":"Fazakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan","family":"Liko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoly","family":"Racz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,16]]},"reference":[{"issue":"5112","key":"323_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993, 260 (5112): 1317-1320. 10.1126\/science.8493574.","journal-title":"Science"},{"issue":"7","key":"323_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/hmg\/10.7.763","volume":"10","author":"CA Friedrich","year":"2001","unstructured":"Friedrich CA: Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet. 2001, 10 (7): 763-767. 10.1093\/hmg\/10.7.763.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"323_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/jmg.33.4.328","volume":"33","author":"ER Maher","year":"1996","unstructured":"Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, Moore AT: Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996, 33 (4): 328-332.","journal-title":"J Med Genet"},{"issue":"8749","key":"323_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/0140-6736(91)91705-Y","volume":"337","author":"HP Neumann","year":"1991","unstructured":"Neumann HP, Wiestler OD: Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991, 337 (8749): 1052-1054. 10.1016\/0140-6736(91)91705-Y.","journal-title":"Lancet"},{"issue":"7","key":"323_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/jmg.28.7.443","volume":"28","author":"ER Maher","year":"1991","unstructured":"Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson-Smith MA, Morton N: Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991, 28 (7): 443-447.","journal-title":"J Med Genet"},{"issue":"20","key":"323_CR6","doi-asserted-by":"publisher","first-page":"11661","DOI":"10.1073\/pnas.95.20.11661","volume":"95","author":"O Iliopoulos","year":"1998","unstructured":"Iliopoulos O, Ohh M, Kaelin WG: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. PNAS. 1998, 95 (20): 11661-11666. 10.1073\/pnas.95.20.11661.","journal-title":"PNAS"},{"issue":"15","key":"323_CR7","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.95.15.8817","volume":"95","author":"A Schoenfeld","year":"1998","unstructured":"Schoenfeld A, Davidowitz EJ, Burk RD: A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. PNAS. 1998, 95 (15): 8817-8822. 10.1073\/pnas.95.15.8817.","journal-title":"PNAS"},{"issue":"5413","key":"323_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.284.5413.455","volume":"284","author":"CE Stebbins","year":"1999","unstructured":"Stebbins CE, Kaelin WG, Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999, 284 (5413): 455-461. 10.1126\/science.284.5413.455.","journal-title":"Science"},{"issue":"6733","key":"323_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999, 399 (6733): 271-275. 10.1038\/20459.","journal-title":"Nature"},{"issue":"7","key":"323_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000, 2 (7): 423-427. 10.1038\/35017054.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"323_CR11","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1073\/pnas.94.6.2156","volume":"94","author":"A Pause","year":"1997","unstructured":"Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD: The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. PNAS. 1997, 94 (6): 2156-2161. 10.1073\/pnas.94.6.2156.","journal-title":"PNAS"},{"issue":"10","key":"323_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/hmg\/10.10.1019","volume":"10","author":"MA Hoffman","year":"2001","unstructured":"Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG: von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001, 10 (10): 1019-1027. 10.1093\/hmg\/10.10.1019.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"323_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/(SICI)1097-0215(19980729)77:3<337::AID-IJC5>3.0.CO;2-P","volume":"77","author":"E van der Harst","year":"1998","unstructured":"van der Harst E, de Krijger RR, Dinjens WN, Weeks LE, Bonjer HJ, Bruining HA, Lamberts SW, Koper JW: Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer. 1998, 77 (3): 337-340. 10.1002\/(SICI)1097-0215(19980729)77:3<337::AID-IJC5>3.0.CO;2-P.","journal-title":"Int J Cancer"},{"issue":"1","key":"323_CR14","first-page":"49","volume":"6","author":"PG Rothberg","year":"2001","unstructured":"Rothberg PG, Bradley JF, Baker DW, Huelsman KM: Is the P25L a \"real\" VHL mutation?. Mol Diagn. 2001, 6 (1): 49-54.","journal-title":"Mol Diagn"},{"issue":"4","key":"323_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF03256462","volume":"10","author":"RK Pettman","year":"2006","unstructured":"Pettman RK, Crowley A, Riddell C, Ludman MD: VHL P25L is not a pathogenic von Hippel-Lindau mutation: a family study. Mol Diagn Ther. 2006, 10 (4): 239-242.","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"323_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/00008469-200410000-00008","volume":"13","author":"A Patocs","year":"2004","unstructured":"Patocs A, Karadi E, Toth M, Varga I, Szucs N, Balogh K, Majnik J, Glaz E, Racz K: Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev. 2004, 13 (5): 403-409. 10.1097\/00008469-200410000-00008.","journal-title":"Eur J Cancer Prev"},{"key":"323_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jmb.2004.04.058","volume":"340","author":"O O'Sullivan","year":"2004","unstructured":"O'Sullivan O, Suhre K, Abergel C, Higgins DG, Notredame C: 3Dcoffee : Combining protein sequences and structures within multiple sequence alignments. J Mol Biol. 2004, 340: 385-395. 10.1016\/j.jmb.2004.04.058.","journal-title":"J Mol Biol"},{"key":"323_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.185.4154.862","volume":"185","author":"R Grantham","year":"1974","unstructured":"Grantham R: Amino acid difference formula to help explain protein evaluation. Science. 1974, 185: 862-864. 10.1126\/science.185.4154.862.","journal-title":"Science"},{"issue":"4","key":"323_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jmg.2005.033878","volume":"43","author":"SV Tavtigian","year":"2006","unstructured":"Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A: Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitution as neutral. J Med Genet. 2006, 43 (4): 295-305. 10.1136\/jmg.2005.033878.","journal-title":"J Med Genet"},{"issue":"5","key":"323_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/nar\/gkj518","volume":"34","author":"E Mathe","year":"2006","unstructured":"Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV: Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res. 2006, 34 (5): 1317-1325. 10.1093\/nar\/gkj518.","journal-title":"Nucleic Acids Res"},{"key":"323_CR21","unstructured":"Website title. [http:\/\/agvgd.iarc.fr]"},{"issue":"15","key":"323_CR22","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/elps.1150181505","volume":"18","author":"N Guex","year":"1997","unstructured":"Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997, 18 (15): 2714-2723. 10.1002\/elps.1150181505.","journal-title":"Electrophoresis"},{"issue":"1","key":"323_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/humu.1380050109","volume":"5","author":"F Chen","year":"1995","unstructured":"Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995, 5 (1): 66-75. 10.1002\/humu.1380050109.","journal-title":"Hum Mutat"},{"issue":"1","key":"323_CR24","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1053\/ajkd.2003.50021","volume":"41","author":"F Assadi","year":"2003","unstructured":"Assadi F, Brackbill EL: Bilateral pheochromocytomas and congenital anomalies associated with a de novo germline mutation in the von Hippel-Lindau gene. Am J Kidney Dis. 2003, 41 (1): E3-10.1053\/ajkd.2003.50021.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"323_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/hmg\/6.7.1051","volume":"6","author":"ER Woodward","year":"1997","unstructured":"Woodward ER, Eng C, McMahon R, Voutilainen R, Affara NA, Ponder BA, Maher ER: Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet. 1997, 6 (7): 1051-1056. 10.1093\/hmg\/6.7.1051.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"323_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s004390050206","volume":"98","author":"D Glavac","year":"1996","unstructured":"Glavac D, Neumann HP, Wittke C, Jaenig H, Masek O, Streicher T, Pausch F, Engelhardt D, Plate KH, Hofler H, et al: Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet. 1996, 98 (3): 271-280. 10.1007\/s004390050206.","journal-title":"Hum Genet"},{"issue":"9","key":"323_CR27","first-page":"3067","volume":"43","author":"H Dollfus","year":"2002","unstructured":"Dollfus H, Massin P, Taupin P, Nemeth C, Amara S, Giraud S, Beroud C, Dureau P, Gaudric A, Landais P, et al: Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophth Vis Sci. 2002, 43 (9): 3067-3074.","journal-title":"Invest Ophth Vis Sci"},{"issue":"8","key":"323_CR28","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/hmg\/3.8.1303","volume":"3","author":"PA Crossey","year":"1994","unstructured":"Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA, et al: Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994, 3 (8): 1303-1308. 10.1093\/hmg\/3.8.1303.","journal-title":"Hum Mol Genet"},{"issue":"1\u20133","key":"323_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-5793(03)01392-9","volume":"556","author":"HA Bluyssen","year":"2004","unstructured":"Bluyssen HA, Lolkema MP, van Beest M, Boone M, Snijckers CM, Los M, Gebbink MF, Braam B, Holstege FC, Giles RH, et al: Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett. 2004, 556 (1\u20133): 137-142. 10.1016\/S0014-5793(03)01392-9.","journal-title":"FEBS Lett"},{"issue":"9","key":"323_CR30","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1074\/jbc.M413160200","volume":"280","author":"F Miller","year":"2005","unstructured":"Miller F, Kentsis A, Osman R, Pan ZQ: Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex. J Biol Chem. 2005, 280 (9): 7985-7996. 10.1074\/jbc.M413160200.","journal-title":"J Biol Chem"},{"issue":"2","key":"323_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0022-2836(02)00442-4","volume":"320","author":"R Guerois","year":"2002","unstructured":"Guerois R, Nielsen JE, Serrano L: Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol. 2002, 320 (2): 369-387. 10.1016\/S0022-2836(02)00442-4.","journal-title":"J Mol Biol"},{"issue":"2","key":"323_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/humu.10309","volume":"23","author":"S Ruiz-Llorente","year":"2004","unstructured":"Ruiz-Llorente S, Bravo J, Cebrian A, Cascon A, Pollan M, Telleria D, Leton R, Urioste M, Rodriguez-Lopez R, de Campos JM, et al: Genetic characterization and structural analysis of VHL Spanish families to define genotype-phenotype correlations. Hum Mutat. 2004, 23 (2): 160-169. 10.1002\/humu.10309.","journal-title":"Hum Mutat"},{"issue":"7","key":"323_CR33","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1136\/jmg.39.7.e38","volume":"39","author":"C Cybulski","year":"2002","unstructured":"Cybulski C, Krzystolik K, Murgia A, Gorski B, Debniak T, Jakubowska A, Martella M, Kurzawski G, Prost M, Kojder I, et al: Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet. 2002, 39 (7): E38-10.1136\/jmg.39.7.e38.","journal-title":"J Med Genet"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-9-29.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2350-9-29\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-9-29","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-9-29.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:49:01Z","timestamp":1630464541000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/1471-2350-9-29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1186\/1471-2350-9-29","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,16]]},"assertion":[{"value":"26 October 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"29"}}